New Peptide-Based Transporter Delivers Cancer-Fighting Molecules Into Human Tumor Cells

The team synthesized the FAT transporter using a revised scalable methodology for δ-azaproline. They characterized its structure using CD spectroscopy, studied cellular uptake in CHO cells using a Bodipy fluorophore conjugate, and tested delivery of two therapeutic cargos in human carcinoma cells using MTT assays and western blot analysis.

Drug delivery remains one of the biggest challenges in cancer therapy — many promising molecules cannot cross cell membranes effectively. This study introduces a proteolytically stable alternative to natural cell-penetrating peptides that could improve the intracellular delivery of peptide drugs and antisense therapeutics, potentially making cancer treatments more effective.

Cell-penetrating peptides are a major area of drug delivery research, but their clinical use has been limited by poor stability and bioavailability. Developing non-natural alternatives like FAT that resist enzymatic degradation could bridge the gap between lab-stage peptide therapeutics and clinical application, particularly for cancer immunotherapy targets like PDL1.

This study was conducted entirely in vitro using cell lines, so it remains unknown whether FAT would perform similarly in living organisms. In vivo challenges such as biodistribution, toxicity, immune response, and pharmacokinetics were not addressed. The study also did not compare FAT's performance quantitatively against established cell-penetrating peptides.